supportsightadmin

About supportsightadmin

This author has not yet filled in any details.
So far supportsightadmin has created 14 blog entries.

Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease

Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic area. Patients receiving gildeuretinol showed 80% slower loss of retinal sensitivity compared to [...]

By |2024-02-13T14:13:56+00:00November 3rd, 2023|

EYLEA HD Injection Approved by FDA for Treatment of Wet Age-Related Macular Degeneration (WAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

August 18, 2023 at 6:35 PM EDT Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment [...]

By |2024-02-13T14:14:59+00:00September 5th, 2023|

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first and only FDA approved treatment for geographic atrophy [...]

By |2024-02-13T14:17:22+00:00July 31st, 2023|

New Treatment for AMD Accepted for FDA Priority Review

February 23, 2023 at 7:00 AM EST AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, [...]

By |2024-02-13T14:18:37+00:00March 7th, 2023|

Next Stop: AMD Central

Dawn Prall and Joshua Dunaief discuss AMD Central, a new site for people living with the condition Recently, I talked to Dawn Prall, founder and executive director of The SupportSight Foundation, and Joshua L. Dunaief, Adele Niessen Professor of Ophthalmology [...]

By |2021-09-17T17:50:12+00:00September 17th, 2021|
Go to Top